Print

Novavax, Inc. (NVAX) Presents RSV Vaccine Data at the 8th Annual International Respiratory Virus Symposium  
9/27/2012 9:58:54 AM

ROCKVILLE, Md., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer, and Ramadevi Raghunandan, Ph.D., Manager, Preclinical Immunology & Discovery, are presenting recent findings from the company's respiratory syncytial virus (RSV) vaccine development program at the 8th Annual International Respiratory Virus Symposium (RSV 2012) meeting in Santa Fe, New Mexico.
//-->